China NMPA Product Recall - Charging kit for patient programmer and implantable neurostimulator

Medtronic (Shanghai) Management Co., Ltd., a subsidiary of Medtronic, Inc., initiated a voluntary Class III recall in China for specific charging kits designed for patient programmers and implantable neurostimulators. This recall, reported to the China National Medical Products Administration (NMPA) on January 19, 2017, and subsequently published on March 1, 2017, addresses a regulatory compliance matter rather than a safety defect. The core issue identified was that the production dates for certain batches of these critical medical devices, specifically models 37746 and 37754 (e.g., NLU028605N, NKU033900N), predated the official approval dates of their registration certificates issued by the NMPA. While the company confirmed that these products were manufactured in strict adherence to all production requirements and pose no risk to patient safety or product efficacy, the recall was mandated to ensure full compliance with Chinese medical device regulatory frameworks. The scope of the recall affects 11 units imported into China, with 9 units having been sold domestically. Medtronic's required actions include distributing notification letters to all affected parties and systematically recalling all unused products. These recalled items will then be disposed of, ensuring adherence to NMPA guidelines and maintaining the integrity of the medical device registration process in China.